Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27030667 | 0.97 | PLA2G7 (0.36) | PLA2G7CRBNBRD4BRD2PKM | |
| SCHEMBL22070 | 0.97 | — | — | |
| Bromide SCHEMBL28907673 | 0.94 | PLA2G7 (0.35) | PLA2G7CRBNBRD4BRD2PKM | |
| Hydrochloric Acid SCHEMBL28447867 | 0.94 | PLA2G7 (0.35) | PLA2G7CRBNBRD4BRD2PKM | |
| Formaldehyde SCHEMBL3082020 | 0.92 | PLA2G7 (0.34) | PLA2G7CRBNBRD4BRD2PKM | |
| SCHEMBL21387942 | 0.92 | PLA2G7 (0.34) | PLA2G7CRBNBRD4BRD2PKM | |
| Bromide SCHEMBL4894442 | 0.92 | PLA2G7 (0.34) | PLA2G7CRBNBRD4BRD2PKM | |
| Silver SCHEMBL27991638 | 0.84 | PKM (0.33) | PLA2G7PKM | |
| SCHEMBL4577654 | 0.79 | HDAC6 (0.35) | CRBNBRD4HDAC6ALDH1A1RECQL | |
| Phenol SCHEMBL11576606 | 0.77 | PLA2G7 (0.44) | PLA2G7BRD4KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023243394-A1 | COMPOSITION, METHOD FOR PRODUCING COMPOSITION, AND METHOD FOR PRODUCING SILVER FILM | 株式会社ADEKA | 2023-12-21 | — | — | WO | disclosed |
| US-9187351-B2 | Water treatment | KING TECHNOLOGY INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2493820-A2 | WATER TREATMENT | King Technology, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| CN-1753702-B | Assembly for producing a medical device having a coating comprising hydrogen peroxide | COLOPLAST AS | 2012-04-18 | — | — | CN | disclosed |
| WO-2011056203-A2 | WATER TREATMENT | KING TECHNOLOGY, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110094972-A1 | Water treatment | KING TECHNOLOGY, INC. | 2011-04-28 | — | — | US | disclosed |
| CN-100574826-C | Packaging for medical devices | COLOPLAST AS | 2009-12-30 | — | — | CN | disclosed |
| CN-101132826-A | Packaging for medical devices | COLOPLAST AS (DK) | 2008-02-27 | — | — | CN | disclosed |
| JP-2004225063-A | NON-CYANOGEN BASE SILVER-PLATING SOLUTION AND SILVER-PLATING METHOD, AND METHOD FOR FORMING BUMP WITH THIS METHOD | ELECTROPLATING ENG OF JAPAN CO | 2004-08-12 | — | — | JP | disclosed |
| EP-1062383-A4 | ELECTROLYTE AND TIN-SILVER ELECTROPLATING PROCESS | LEARONAL INC (US) | 2002-08-14 | — | — | EP | disclosed |
| US-6210556-B1 | FOR DEPOSITING TIN-RICH TIN-SILVER ALLOYS UPON A SUBSTRATE | LEARONAL, INC. | 2001-04-03 | — | — | US | disclosed |
| EP-1062383-A1 | ELECTROLYTE AND TIN-SILVER ELECTROPLATING PROCESS | LeaRonal, Inc. (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999041433-A1 | ELECTROLYTE AND TIN-SILVER ELECTROPLATING PROCESS | LEARONAL, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110094972-A1 | Water treatment | HNMT, NAAA, MPO | PLA2G7 2331/4885CRBN 4326/4885BRD4 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.